Interferon a (human leukocyte protein moiety reduced). A type I interferon consisting of 165 amino acid residues with lysine in position 23. This protein is produced by recombinant DNA technology and resembles interferon secreted by leukocytes. It is used extensively as an antiviral or antineoplastic agent. An oral form is being developed by Amarillo Biosciences.
This report contains market size and forecasts of Interferon Alpha-2a Biosimilar in global, including the following market information:
Global Interferon Alpha-2a Biosimilar Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global Interferon Alpha-2a Biosimilar Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five Interferon Alpha-2a Biosimilar companies in 2021 (%)
The global Interferon Alpha-2a Biosimilar market was valued at 217.1 million in 2021 and is projected to reach US$ 99.7 million by 2028, at a CAGR of -10.5% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
Long-lasting Type Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of Interferon Alpha-2a Biosimilar include Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED and 3sbio, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the Interferon Alpha-2a Biosimilar manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Interferon Alpha-2a Biosimilar Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Interferon Alpha-2a Biosimilar Market Segment Percentages, by Type, 2021 (%)
Long-lasting Type
Ordinary Type
Global Interferon Alpha-2a Biosimilar Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Interferon Alpha-2a Biosimilar Market Segment Percentages, by Application, 2021 (%)
Hepatitis C
Hepatitis B
Others
Global Interferon Alpha-2a Biosimilar Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global Interferon Alpha-2a Biosimilar Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Interferon Alpha-2a Biosimilar revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies Interferon Alpha-2a Biosimilar revenues share in global market, 2021 (%)
Key companies Interferon Alpha-2a Biosimilar sales in global market, 2017-2022 (Estimated), (K Units)
Key companies Interferon Alpha-2a Biosimilar sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Roche
Biosidus
Zydus Cadila
Nanogen
Amega Biotech
Rhein Minapharm Biogenetics
PROBIOMED
3sbio

LEAVE A REPLY

Please enter your comment!
Please enter your name here